Financial Performance - The company reported a revenue of HKD 49.1 million for the fiscal year ending March 31, 2024, representing a 7.9% increase from HKD 45.5 million in the previous fiscal year[8]. - The company recorded a loss attributable to shareholders of HKD 3.0 million, a decrease of 13.8% compared to a loss of HKD 3.5 million in the previous year[8]. - Basic loss per share for the year was HKD 0.77, down 13.5% from HKD 0.89 in the previous year[8]. - The company experienced over 20% revenue growth in the first half of the fiscal year, although this momentum slowed down later in the year[7]. - The group's revenue increased by HKD 3.6 million or 7.9% to HKD 49.1 million for the year ending March 31, 2024, compared to HKD 45.5 million for the previous year[18]. - Revenue from medical consultation services, prescription and dispensing services, and treatment services accounted for 2.3%, 19.2%, and 78.5% of total revenue, respectively[15]. Operational Challenges - The company continues to face intense competition and rising operational costs but remains committed to maintaining high standards and competitiveness in its services and products[8]. - The company acknowledges the impact of a slowing Chinese economy and high interest rates on business confidence, affecting consumer spending behavior[7]. - The group anticipates continued challenges due to adverse economic conditions but aims to adapt and monitor market changes proactively[17]. - The company has implemented cost-saving measures and improved operational efficiency to enhance performance amid challenges[8]. Strategic Focus - The company aims to strategically expand and strengthen its market share in Hong Kong and mainland China while enhancing service and product quality[11]. - The company is focused on exploring and launching new services and products to increase market share and identify new business opportunities[9]. - The group introduced new treatment technologies, including EMFACE® Submentum and SYLFIRM X™, enhancing its service offerings[13]. Employee and Cost Management - Employee costs increased by HKD 1.4 million or 6.2% to HKD 24.6 million for the year ending March 31, 2024, due to increased salaries and performance bonuses[22]. - Other expenses rose by HKD 1.4 million or 18.4% to HKD 9.0 million, aligning with the increase in revenue[25]. - Inventory costs for the years ending March 31, 2024, and 2023 were HKD 9.7 million and HKD 8.9 million, representing 19.8% and 19.5% of total revenue, respectively[20]. Shareholder Relations - The company expresses gratitude to shareholders, business partners, suppliers, and customers for their support during the year[9]. - The company did not recommend any final dividend for the year ending March 31, 2024, consistent with 2023[60]. - The company’s distributable reserves as of March 31, 2024, amounted to HKD 1.1 million[71]. Governance and Compliance - The audit committee has reviewed the audited consolidated financial statements for the year ending March 31, 2024, ensuring compliance with applicable accounting standards and GEM listing rules[99]. - The company has adopted corporate governance practices in line with GEM listing rules and has not deviated from the corporate governance code during the fiscal year[108]. - The company has established three committees: the audit committee, the remuneration committee, and the nomination committee, to oversee specific aspects of corporate governance[133]. Environmental, Social, and Governance (ESG) Initiatives - The company’s environmental, social, and governance report covers operations from April 1, 2023, to March 31, 2024, focusing on its medical skin care centers in Hong Kong, which contribute nearly all of its revenue[174][175]. - The total greenhouse gas emissions for the group in 2024 were 50,636 kg CO2 equivalent, a decrease from 52,136 kg in 2023, representing a reduction of approximately 2.9%[198]. - The group has established key performance indicators for measuring its environmental and social performance, ensuring consistency in statistical methods for meaningful comparisons[178]. - The group aims to integrate sustainability into its core business values and continuously review progress against ESG-related goals[183]. Risk Management - The company has implemented a risk management and internal control system, which was reviewed by the audit committee for effectiveness[136]. - The board believes that the internal control measures are adequate to effectively monitor business operations for the fiscal year ending March 31, 2024[153]. - The company has a risk management framework that includes processes for risk identification, analysis, assessment, treatment, and monitoring[151].

Financial Performance - The company reported a revenue of HKD 49.1 million for the fiscal year ending March 31, 2024, representing a 7.9% increase from HKD 45.5 million in the previous fiscal year[13]. - The company recorded a loss attributable to owners of HKD 3.0 million, a decrease of HKD 0.5 million or 13.8% compared to a loss of HKD 3.5 million for the fiscal year ending March 31, 2023[13]. - Basic loss per share for the year was HKD 0.77, a reduction of 13.5% from HKD 0.89 in the previous year[13]. - The company experienced over 20% revenue growth in the first half of the fiscal year, although this momentum slowed down later in the year[13]. - The company noted increased competition within the industry and rising operational costs[14]. - The company's revenue increased by HKD 3.6 million or 7.9% to HKD 49.1 million for the year ended March 31, 2024, compared to HKD 45.5 million for the previous year[24]. Operational Challenges - The company faced challenges due to a slowdown in the Chinese economy, high interest rates, and a stagnant local real estate and stock market[13]. - Consumer sentiment has become more cautious, impacting the company's industry negatively[13]. - Cost-saving measures and operational efficiency improvements have been implemented to address the challenges faced by the company[14]. - The management anticipates ongoing challenges due to adverse economic conditions but remains committed to adapting strategies to maintain service quality and market position[23]. Revenue Breakdown - Revenue from medical consultation services, prescription and dispensing services, and treatment services accounted for 2.3%, 19.2%, and 78.5% of total revenue, respectively[21]. Employee and Operational Costs - Employee costs increased by HKD 1.4 million or 6.2% to HKD 24.6 million for the year ended March 31, 2024, primarily due to increased salaries and performance bonuses[28]. - Other expenses increased from HKD 7.6 million for the year ending March 31, 2023, to HKD 9.0 million for the year ending March 31, 2024, representing an increase of HKD 1.4 million or 18.4%[31]. - The company has implemented cost-saving measures to improve operational efficiency amid rising operational costs and intense competition[18]. Financial Position - The total equity of the company as of March 31, 2024, was HKD 7.6 million, down from HKD 10.6 million as of March 31, 2023[35]. - The company had cash and bank balances of HKD 6.9 million as of March 31, 2024, compared to HKD 5.0 million as of March 31, 2023, with over 96% held in HKD[35]. - Operating cash generated for the year ending March 31, 2024, was HKD 11.0 million, up from HKD 4.3 million for the previous year[37]. - The company had no interest-bearing borrowings as of March 31, 2024, resulting in a debt-to-equity ratio of zero[35]. - The company has unused bank financing of HKD 18.0 million under the SME Financing Guarantee Scheme as of March 31, 2024[37]. Governance and Compliance - The company has maintained compliance with all relevant laws and regulations without any significant violations during the fiscal year ending March 31, 2024[63]. - The company has adopted the corporate governance code as per GEM Listing Rules Appendix C1 and has complied with it for the year ending March 31, 2024[114]. - The audit committee has reviewed the audited consolidated financial statements for the year ending March 31, 2024, ensuring compliance with applicable accounting standards and GEM listing rules[105]. - The company has established a shareholder communication policy to ensure timely and comprehensive information is provided to shareholders and investors, which is reviewed at least annually[165]. Sustainability and ESG - The environmental, social, and governance report covers the company's performance in these areas for the period from April 1, 2023, to March 31, 2024, focusing on its medical skin care services in Hong Kong[180]. - The company aims to integrate sustainability into its core business values and will continue to review progress based on environmental, social, and governance-related goals[189]. - The company has complied with the "comply or explain" provisions of the environmental, social, and governance reporting guidelines for the fiscal year ending March 31, 2024[190]. - The company conducted an annual materiality assessment to identify and understand stakeholders' main concerns regarding environmental, social, and governance issues[196]. Board and Management Structure - The board consists of four executive directors and three independent non-executive directors as of March 31, 2024[116]. - The company has established a remuneration committee to review and recommend compensation policies for directors and senior management based on performance and market comparisons[88]. - The company has appointed at least three independent non-executive directors as required by GEM listing rules, and established an audit committee with a majority of independent members[133]. - The company has a clear division of responsibilities between the board and management to maintain control over key decisions[119].

Financial Performance - The company's revenue for the six months ended September 30, 2023, was HKD 24,555,000, representing a 22.0% increase compared to HKD 20,021,000 for the same period last year[4]. - The company reported a loss before tax of HKD 2,145,000 for the six months ended September 30, 2023, which is a 35.7% reduction from a loss of HKD 3,331,000 in the same period last year[4]. - The total comprehensive loss for the six months ended September 30, 2023, was HKD 2,099,000, down from HKD 3,277,000 in the previous year, reflecting a 36.0% improvement[16]. - The company reported a net loss attributable to shareholders of HKD 2,123 thousand for the six months ended September 30, 2023, compared to a loss of HKD 3,305 thousand for the same period in 2022, representing a 35.7% improvement[33]. - Revenue from medical consultation services increased to HKD 589 thousand, up 18.7% from HKD 496 thousand in the previous year[26]. - Total revenue for the six months ended September 30, 2023, was HKD 24,555 thousand, a 22.0% increase compared to HKD 20,021 thousand in the same period of 2022[26]. - The basic loss per share for the six months ended September 30, 2023, was HKD 0.54, compared to HKD 0.83 for the same period last year, showing an improvement in per-share loss metrics[16]. - The company's basic loss per share for the period was HKD 0.54, a reduction of 34.9% from HKD 0.83 in the previous year[73]. Cash Flow and Assets - The operating cash generated for the three months ended September 30, 2023, was HKD 2,831,000, compared to HKD 862,000 for the same period in 2022, indicating a significant improvement[10]. - The company's cash and cash equivalents at the end of the reporting period were HKD 3,351,000, a decrease from HKD 9,751,000 at the end of the previous year[10]. - As of September 30, 2023, total assets amounted to HKD 24,912 thousand, a decrease of 6.7% from HKD 26,713 thousand as of March 31, 2023[18]. - The company reported a decrease in total liabilities to HKD 28,681 thousand as of September 30, 2023, down from HKD 29,291 thousand as of March 31, 2023[18]. - The net asset value as of September 30, 2023, was HKD 9,037 thousand, a decline of 19.0% from HKD 11,160 thousand as of March 31, 2023[18]. - The group’s bank balance and cash as of September 30, 2023, was HKD 3.4 million, a decrease from HKD 5.0 million as of March 31, 2023, with no external borrowings[130]. - Time deposits amounted to HKD 13.6 million as of September 30, 2023, slightly down from HKD 13.9 million as of March 31, 2023[131]. Liabilities and Equity - The net current liabilities of the group were HKD 3.8 million, primarily due to contract liabilities of HKD 18.5 million, which are expected to be fulfilled without cash outflow[12]. - The net current liabilities of the group as of September 30, 2023, stood at HKD 3.8 million, an increase from HKD 2.6 million as of March 31, 2023[130]. - As of September 30, 2023, the total equity of the group was HKD 9.0 million, down from HKD 11.2 million as of March 31, 2023[130]. - The company has no interest-bearing borrowings, resulting in a capital debt ratio of zero as of September 30, 2023[76]. Operational Highlights - The company continues to focus on providing medical consultation services, prescription and dispensing services, and treatment services as its primary revenue sources[13]. - The group operates a single business segment focused on medical consultation services, prescription and dispensing services, and treatment services[46]. - The group operates two "Medicskin" brand medical skin care centers in prime locations in Hong Kong, focusing on treating skin diseases and improving customer appearance[67]. - The group continues to face intense competition and rising operational costs, impacting consumer sentiment amid ongoing economic challenges[45]. Employee and Costs - Employee costs increased to HKD 12,511 thousand for the six months ended September 30, 2023, up from HKD 10,420 thousand in the previous year, reflecting a 20.0% rise[30]. - The group employed 28 full-time and 16 part-time employees as of September 30, 2023, with total employee costs amounting to HKD 12.5 million for the six months ended September 30, 2023, compared to HKD 10.4 million for the same period in 2022[115]. - Employee costs rose by HKD 2.1 million or 20.1% to HKD 12.5 million, primarily due to increased salaries and performance bonuses linked to revenue growth[92]. Governance and Compliance - The company has maintained its accounting policies consistent with those used in the preparation of the financial statements for the year ended March 31, 2023[11]. - The audit committee reviewed the group's unaudited interim financial statements for the six months ended September 30, 2023, and found them compliant with applicable accounting standards and GEM listing rules[111]. - The company has adopted corporate governance practices in accordance with the GEM listing rules and has complied with them during the reporting period[108]. - The board of directors believes that the current structure does not undermine the balance of power and authority between the board and the management of the group[119]. Future Outlook - The company remains cautiously optimistic about future performance, anticipating a recovery in sales due to the resumption of normal social and economic activities[90]. - The company anticipates that the application of new accounting standards will not have a significant impact on its financial statements in the foreseeable future[23]. Dividends and Share Options - The company did not declare an interim dividend for the six months ended September 30, 2023, consistent with the previous year[32]. - The company has adopted a share option scheme since December 3, 2014, to reward and/or incentivize eligible individuals for their contributions to the group[115]. - There were no share options granted, exercised, lapsed, or cancelled during the six months ended September 30, 2023[122]. Related Party Transactions - The group has not entered into any transactions with related parties during the six months ended September 30, 2023[43]. - The group reported no individual customer contributing over 10% of total revenue during the six months ended September 30, 2023[48].

香港交易及結算所有限公司及香港聯合交易所有限公司（「聯交所」）對本公告的內容概不 負責，對其準確性或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何 部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 （於開曼群島註冊成立的有限公司） （股份代號：8307） 截至2023年9月30日止六個月之 中期業績公告 密迪斯肌控股有限公司（「本公司」）之董事（「董事」）會（「董事會」）欣然公佈本公司及其附 屬公司（統稱「本集團」）截至2023年9月30日止六個月之未經審核簡明綜合中期業績連同 去年同期之未經審核比較數字。本公告載有本公司2023/24中期報告全文，符合聯交所 GEM證券上市規則（「GEM上市規則」）有關隨附中期業績初步公告的資料的相關規定。 本公告刊載於聯交所網站(www.hkexnews.hk)及本公司網站(www.medicskinholdings.com)。 本公司2023/24中期報告印刷本將適時寄發予本公司股東，並於本公司及聯交所網站可供查 閱。 承董事會命 密迪斯肌控股有限公司 主席兼執行董事 江覺亮醫生 ...

Financial Performance - The company reported a revenue of HKD 12,912 thousand for the three months ended June 30, 2023, representing a 23.3% increase from HKD 10,467 thousand in the same period of 2022[4] - The loss before tax for the period was HKD 550 thousand, compared to a loss of HKD 799 thousand in the previous year, indicating a 30.9% improvement[4] - The basic and diluted loss per share was HKD 0.14, an improvement from HKD 0.20 in the same quarter of the previous year[4] - The total comprehensive loss for the period was HKD 530 thousand, compared to HKD 792 thousand in the previous year, showing a 33.0% reduction[6] - The company reported a loss attributable to owners of the company of HKD 539 million for the three months ended June 30, 2023, compared to a loss of HKD 786 million for the same period in 2022, representing a 31.5% improvement[26] - The loss attributable to the company's owners for the three months ended June 30, 2023, was HKD 0.5 million, a decrease of HKD 0.3 million or 31.4% from HKD 0.8 million for the same period in 2022[57] - Basic loss per share for the period was HKD 0.14, down 30.0% from HKD 0.20 in the previous year[57] Revenue Breakdown - The revenue from medical consultation services was HKD 303 thousand, up from HKD 225 thousand, reflecting a 34.7% increase year-over-year[9] - The revenue from prescription and dispensing services increased to HKD 2,489 thousand from HKD 2,077 thousand, marking a 19.9% growth[9] - The revenue from treatment services rose to HKD 10,120 thousand, compared to HKD 8,165 thousand, which is a 24.0% increase[9] - Advisory service revenue increased to HKD 167,000 for the three months ended June 30, 2023, up from HKD 51,000 in the same period of 2022, marking a significant increase of 227.5%[22] - The revenue breakdown includes HKD 0.3 million from medical diagnosis services, HKD 2.5 million from prescription and dispensing services, and HKD 10.1 million from treatment services, accounting for 2.3%, 19.3%, and 78.4% of total revenue respectively[60] Operational Insights - The company operates primarily in Hong Kong, with nearly all revenue generated from external customers located there[20] - The company is focused on expanding its services in medical consultation, prescription and dispensing, and treatment services[19] - The company plans to continue market research and evaluation of new products, skills, and treatment technologies to drive business growth and maintain competitiveness[45] - The company maintains a cautious optimism regarding future performance, anticipating a recovery in local consumer sentiment and sales due to the lifting of COVID-19 restrictions and the resumption of cross-border travel with mainland China[58] - The company aims to strengthen its market position and identify new business opportunities to enhance brand development and maximize returns for investors[58] Cost and Expenses - Employee costs rose by HKD 1.4 million or 28.3% to HKD 6.3 million for the three months ended June 30, 2023, primarily due to increased revenue leading to higher salaries and performance bonuses for doctors[47] - Other income, losses, and expenses increased to a net loss of HKD 167,000, up HKD 124,000 or 288.4% from HKD 43,000 in the previous year, primarily due to the absence of government subsidies[61] - Other expenses rose by HKD 0.2 million or 12.0% to HKD 2.0 million, consistent with the increase in revenue[65] - For the three months ended June 30, 2023, the group's cost of used inventory was HKD 2.4 million, compared to HKD 2.0 million for the same period in 2022, representing 18.7% of revenue for both periods[89] Corporate Governance - The company has adopted a share option scheme to reward and/or return contributions from eligible individuals, compliant with GEM Listing Rules Chapter 23[84] - As of June 30, 2023, there were no unexercised share options under the share option scheme[85] - The company is committed to appointing sufficient independent non-executive directors to comply with GEM Listing Rules within three months from June 7, 2023[82] - The board of directors includes both executive and independent non-executive members, ensuring oversight and balance in decision-making processes[87] - The company has acknowledged the need to maintain a positive relationship between executive and non-executive directors to enhance operational efficiency[81] - The board will regularly meet to discuss significant matters affecting the group's operations[81] - The company has confirmed compliance with applicable laws and sufficient disclosures have been made[88] Tax and Liabilities - The company did not incur any tax provisions for Hong Kong profits tax during the periods as there were no estimated taxable profits[66] - The company has a net current liability of HKD 3.0 million as of June 30, 2023, primarily due to contract liabilities of HKD 19.3 million, which are expected to be fulfilled without cash outflow[32] Market Presence - The company operates two "Medicskin" brand medical skin care centers in prime locations in Hong Kong, focusing on treating skin diseases and improving customer appearance[42] - The company has not reported any significant impact from the new Hong Kong Financial Reporting Standards that came into effect on April 1, 2023[7] - The company has no major customers contributing more than 10% of total revenue for the three months ended June 30, 2023, and 2022, indicating a diversified customer base[33]

香港交易及結算所有限公司及香港聯合交易所有限公司（「聯交所」）對本公告的內容概不 負責，對其準確性或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何 部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 （於開曼群島註冊成立的有限公司） （股份代號：8307） 截至2023年6月30日止三個月之 第一季度業績公告 密迪斯肌控股有限公司（「本公司」）之董事（「董事」）會（「董事會」）欣然公佈本公司及其附 屬公司（統稱「本集團」）截至2023年6月30日止三個月之未經審核簡明綜合第一季度業績連 同去年同期之未經審核比較數字。本公告載有本公司2023/24第一季度報告全文，符合聯 交所GEM證券上市規則（「GEM上市規則」）有關隨附第一季度業績初步公告的資料的相關 規定。 本公告刊載於聯交所網站(www.hkexnews.hk)及本公司網站(www.medicskinholdings.com)。 本公司2023/24第一季度報告印刷本將適時寄發予本公司股東，並於本公司及聯交所網站可 供查閱。 承董事會命 密迪斯肌控股有限公司 主席兼執行董事 ...

Environmental Impact - Total greenhouse gas emissions for 2023 were 52,136 kg (CO2 equivalent), an increase from 48,413 kg in 2022, with emissions per employee rising to 1,212 kg from 1,181 kg[12]. - Scope 2 emissions from purchased electricity amounted to 45,363 kg in 2023, up from 42,792 kg in 2022[12]. - The density of greenhouse gas emissions per million HKD of total revenue increased to 1,145 kg in 2023 from 986 kg in 2022[12]. - The company produced 672 kg of indirect emissions from paper waste disposal in 2023, compared to 576 kg in 2022[12]. - The company generated approximately 39 kg of medical waste per employee in 2023, a decrease from 41 kg in 2022, with a density of 0.9 kg per million HKD of total revenue[16]. - The company is committed to sustainable long-term actions to manage its carbon footprint and reduce emissions[13]. - The company has not faced any environmental claims, lawsuits, or penalties during the reporting period[9]. - The company has implemented energy-saving measures, including monitoring indoor temperatures and upgrading to energy-efficient LED lighting[13]. - The company aims to maintain a comfortable indoor temperature of 25 degrees Celsius to balance comfort and energy consumption[13]. - The company has implemented waste reduction strategies and promotes recycling and waste segregation to minimize environmental impact[31]. - The company is committed to managing medical waste carefully, adhering to local regulations regarding waste disposal[26]. - The company has installed HEPA air purifiers in its Medicskin centers to improve indoor air quality[114]. - The group is committed to long-term sustainability by minimizing environmental impact through energy and water conservation efforts[137]. Financial Performance - The company's revenue for the fiscal year ending March 31, 2023, was HKD 45.5 million, a decrease of 7.3% from HKD 49.1 million in the previous fiscal year[49]. - The company recorded a loss attributable to shareholders of HKD 3.0 million, compared to a profit of HKD 3.9 million in the previous fiscal year, primarily due to a revenue decrease of approximately HKD 3.6 million and a foreign exchange loss of HKD 1.4 million[56]. - Other income and net gains decreased from HKD 1.2 million for the year ended March 31, 2022, to HKD 0.5 million for the year ended March 31, 2023, primarily due to a foreign exchange loss of HKD 1.4 million[59]. - Inventory costs increased to HKD 8.9 million for the year ended March 31, 2023, from HKD 7.0 million for the year ended March 31, 2022, representing 19.5% and 14.3% of the group's revenue for the respective years[60]. - Employee costs rose by HKD 2.0 million or 9.5% to HKD 22.5 million for the year ended March 31, 2023, attributed to increased salaries and performance bonuses for doctors[61]. - The group recorded a loss attributable to owners of HKD 3.0 million for the year ended March 31, 2023, compared to a profit of HKD 3.9 million for the year ended March 31, 2022[89]. - Total equity as of March 31, 2023, was HKD 11.2 million, down from HKD 14.2 million as of March 31, 2022[92]. - Cash and bank balances decreased to HKD 5.0 million as of March 31, 2023, from HKD 14.2 million as of March 31, 2022[92]. - The group did not declare a final dividend for the year ended March 31, 2023[91]. - The group had no interest-bearing borrowings as of March 31, 2023, resulting in a debt-to-equity ratio of zero[92]. - Operating cash generated for the year ended March 31, 2023, was HKD 4.3 million, unchanged from 2022[93]. - As of March 31, 2023, the group's lease liabilities were HKD 11.9 million, down from HKD 18.7 million in 2022[93]. - The group has unused bank financing of HKD 18.0 million under the SME Financing Guarantee Scheme as of March 31, 2023, compared to none in 2022[93]. - The capital commitment for injection to subsidiaries was HKD 0.5 million as of March 31, 2023, down from HKD 0.6 million in 2022[97]. - The group has no major investments or capital asset plans as of March 31, 2023[95]. Market and Business Strategy - The group aims to reduce emission intensity by 5% to 10% by 2023, using the fiscal year ending in 2018 as the baseline[26]. - The introduction of the EMFACE® treatment, a revolutionary facial treatment using RF and HIFESTM technology, aims to enhance service offerings and maintain competitiveness in the skincare industry[25]. - The reopening of the border between mainland China and Hong Kong is expected to attract more tourists, potentially positively impacting the group's revenue[26]. - The group plans to continue exploring and launching various new services and products to increase market share and create value for shareholders[25]. - The company plans to strategically expand and strengthen its market share in Hong Kong and mainland China while continuously improving service and product quality[51]. - The company aims to introduce new services and products as a key driver for business growth and to maintain its competitive position in the industry[57]. - The company has implemented measures to enhance online consultation services and e-commerce platforms for skincare products to adapt to the new normal[53]. - The company continues to evaluate market developments in new products, skills, and treatment technologies to provide the most suitable services to customers[57]. Employee and Training - The group has maintained a zero record for work-related injuries and fatalities during the reporting period[112]. - The company provided a total of 235 hours of training for employees during the reporting period, an increase from 171.5 hours in 2022[118]. - 100% of doctors and senior management participated in training, while 50% of general staff and 95% of medical assistants were trained[118]. - The average training hours completed per employee were 11.5 hours for male doctors and 7 hours for female doctors[118]. - The group had a total of 43 employees as of March 31, 2023, compared to 41 employees in the previous year[72]. - As of March 31, 2023, the group employed 28 full-time and 15 part-time employees, with total employee costs amounting to HKD 22.5 million, an increase from HKD 20.5 million in 2022[133]. Governance and Compliance - The group has complied with all relevant laws and regulations regarding environmental protection, health and safety, and employment during the reporting period[138]. - The company has established a whistleblowing policy to report misconduct, ensuring confidentiality and protection for whistleblowers[163]. - The company has received annual confirmation letters regarding the independence of all independent non-executive directors as per GEM Listing Rule 5.09[181]. - The group has maintained effective governance practices, ensuring the independence of its board members and adherence to regulatory requirements[181][184]. - The company has not been aware of any corruption lawsuits against it or its employees during the reporting period[161]. - The company has complied with the Prevention of Bribery Ordinance (Cap. 201) for the year ended March 31, 2023[164]. - Over 40% of employees have attended anti-corruption training provided by the Hong Kong Independent Commission Against Corruption[160]. - The company has established a clear recruitment process to comply with legal requirements and verify candidates' qualifications[119]. Community Engagement - The company donated HKD 3,000 to the Bright Eyes Engineering Charity Fund, demonstrating its commitment to positively impacting the community[186]. - The company emphasizes the importance of community engagement and resource utilization to support organizations driving positive social change[186].

香港交易及結算所有限公司及香港聯合交易所有限公司（「聯交所」）對本公告的內容概不 負責，對其準確性或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何 部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 （於開曼群島註冊成立的有限公司） （股份代號：8307） 截至2023年3月31日止年度之 全年業績公告 密迪斯肌控股有限公司（「本公司」）之董事（「董事」）會（「董事會」）欣然公佈本公司及其附 屬公司（統稱「本集團」）截至2023年3月31日止年度之全年業績連同去年之比較數字。本 公告載有本公司2022/23年年度報告全文，符合聯交所GEM證券上市規則（「GEM上市規 則」）有關隨附全年業績初步公告的資料的相關規定。 本 公 告 刊 載 於 聯 交 所 網 站 (www.hkexnews.hk) 及 本 公 司 網 站 (www.medicskinholdings.com)。本公司2022/23年年度報告印刷本將適時寄發予本公司股 東，並於本公司及聯交所網站可供查閱。 承董事會命 密迪斯肌控股有限公司 主席兼執行董事 江覺亮醫生 ...

Financial Performance - The company reported a loss attributable to owners of the company of HKD 3.1 million for the nine months ended December 31, 2022, compared to a profit of HKD 3.2 million for the same period in 2021, primarily due to a decrease in revenue of approximately HKD 8.3 million or 20.5%[13] - Basic loss per share for the period was HKD 0.79, compared to a basic earnings per share of HKD 0.81 for the same period last year[13] - The company’s total revenue for the nine months ended December 31, 2022, was HKD 31.9 million, a decrease from HKD 40.2 million in the same period last year[58] - The group recorded a net loss of HKD 3.14 million for the nine months ended December 31, 2022, compared to a profit of HKD 3.22 million in the same period of 2021[77] - The group's revenue decreased by HKD 8.3 million or 20.5% to HKD 31.9 million for the nine months ended December 31, 2022, compared to HKD 40.2 million for the same period in 2021[83] Revenue Breakdown - Revenue from medical consultation services for the three months ended December 31, 2022, was HKD 227,000, a decrease of 26% from HKD 306,000 in the same period of 2021[62] - Revenue from prescription and dispensing services for the nine months ended December 31, 2022, was HKD 6.94 million, down 10.6% from HKD 7.76 million in the same period of 2021[62] - Revenue from medical consultation services, prescription and dispensing services, and treatment services were HKD 0.7 million, HKD 6.9 million, and HKD 24.3 million, respectively, accounting for 2.3%, 21.7%, and 76.0% of total revenue[108] Cost and Expenses - The cost of inventory for the group was HKD 6.1 million and HKD 6.2 million for the nine months ended December 31, 2022, and 2021, respectively, representing 19.0% and 15.5% of the group's revenue for the respective periods[15] - Other expenses decreased by HKD 0.7 million or 10.6% compared to the nine months ended December 31, 2021, which amounted to HKD 6.5 million[17] - Employee costs decreased by HKD 1.8 million or 10.8% to HKD 15.5 million for the nine months ended December 31, 2022, primarily due to reduced salaries and bonuses[38] Future Outlook - The company maintains a cautious optimism regarding future performance, anticipating a significant rebound in local consumer sentiment and sales due to the lifting of COVID-19 restrictions[14] - The company aims to continue providing high-quality medical skin care services and products while seeking new business opportunities to enhance its market position and maximize returns for investors[14] - The group believes that introducing new services and products is one of the key drivers for business growth and maintaining competitiveness[109] Market Presence - The company’s revenue from external customers is primarily derived from Hong Kong, indicating a focused market presence[28] - The company has a solid customer base, with most clients having been with the company for over five years, contributing to its revenue stability[12] - The group did not have any individual customer contributing more than 10% of total revenue during the nine months ended December 31, 2022[9] Operational Developments - The company has implemented measures to enhance online consultation services and e-commerce platforms for skincare products in response to the pandemic[35] - The group continues to face intense market competition and the negative impact of the COVID-19 pandemic[80] - The group will continue to conduct market research on the latest products, skills, and medical instruments and technologies[109] Governance and Compliance - The audit committee currently consists of two independent non-executive directors, ensuring compliance with GEM listing rules[123] - The company has established an audit committee and has developed a written terms of reference in accordance with GEM listing rules[123] - The company is committed to appointing sufficient independent non-executive directors to meet the minimum requirements of GEM listing rules within three months from November 15, 2022[121] Other Financial Information - The company did not recommend the payment of an interim dividend for the nine months ended December 31, 2022, consistent with the previous year[31] - Interest income from bank deposits for the nine months ended December 31, 2022, was HKD 233,000, an increase of 6.4% from HKD 219,000 in the same period of 2021[64] - The group received government grants amounting to HKD 829,000 for the nine months ended December 31, 2022[64] - The group reported a foreign exchange loss of HKD 1.52 million for the nine months ended December 31, 2022, compared to a gain of HKD 432,000 in the same period of 2021[64] - The group has not recognized any provision for Hong Kong profits tax due to estimated taxable profits being offset by estimated prior tax losses[86] - The company has not purchased, sold, or redeemed any of its listed securities during the nine months ended December 31, 2022[47] - As of December 31, 2022, the group's current liabilities net amount was HKD 3.2 million, primarily from contract liabilities of HKD 20.1 million[61] - As of December 31, 2022, no share options were exercised or cancelled, and 4,000,000 share options expired[95] - The company has adopted a share option scheme to reward eligible individuals for their contributions to the group[23]

Financial Performance - Revenue for the six months ended September 30, 2022, was HKD 20,021,000, a decrease of 24.5% compared to HKD 26,618,000 for the same period in 2021[4] - The company reported a loss of HKD 3,331,000 for the six months ended September 30, 2022, compared to a profit of HKD 1,900,000 for the same period in 2021[4] - Basic loss per share for the six months ended September 30, 2022, was HKD (0.63), compared to HKD 0.06 for the same period in 2021[6] - The group reported a loss of HKD (3,305) thousand in total comprehensive income for the period, compared to a loss of HKD (3,313) thousand in the previous year[11] - For the six months ended September 30, 2022, the company reported a loss attributable to owners of the company of HKD 3,305,000, compared to a profit of HKD 1,755,000 for the same period in 2021[33] - The group recorded a loss attributable to owners of the company of HKD 3.3 million for the six months ended September 30, 2022, compared to a profit of HKD 1.8 million for the same period in 2021[65] Assets and Liabilities - Total assets decreased to HKD 25,744,000 as of September 30, 2022, down from HKD 30,091,000 as of March 31, 2022[9] - The company's net asset value was HKD 10,866,000 as of September 30, 2022, compared to HKD 14,179,000 as of March 31, 2022[9] - The company’s total liabilities as of September 30, 2022, were HKD 28,266,000, slightly down from HKD 29,863,000 as of March 31, 2022[9] - Total equity as of September 30, 2022, was HKD 10.9 million, down from HKD 14.2 million as of March 31, 2022[81] Cash Flow - The operating cash generated was HKD 862 thousand, down from HKD 1,860 thousand in the previous year, reflecting a decline of 53.8%[14] - The net cash used in investing activities was HKD (758) thousand, compared to HKD (1,547) thousand in the prior year, indicating a reduction of 51%[14] - The net cash used in financing activities was HKD (3,851) thousand, a decrease from HKD (13,945) thousand in the previous year, showing a significant improvement[14] - Cash and bank balances as of September 30, 2022, were HKD 9.8 million, a decrease from HKD 14.2 million as of March 31, 2022[81] Employee Costs - The company incurred employee costs of HKD 10,420,000 for the six months ended September 30, 2022, a decrease of 10.1% from HKD 11,591,000 for the same period in 2021[4] - Total employee costs amounted to HKD 10,420 thousand, a decrease from HKD 11,591 thousand in the previous year, indicating a reduction of 10.1%[26] - Employee costs decreased by HKD 1.2 million or 10.1% to HKD 10.4 million for the six months ended September 30, 2022, compared to HKD 11.6 million for the same period in 2021[72] Revenue Breakdown - The revenue breakdown includes medical consultation services at HKD 0.5 million (2.5%), prescription and dispensing services at HKD 4.4 million (22.2%), and treatment services at HKD 15.1 million (75.3%) for the six months ended September 30, 2022[64] - The group's revenue for the six months ended September 30, 2022, decreased by HKD 6.6 million or 24.8% to HKD 20.0 million, compared to HKD 26.6 million for the same period in 2021[69] Government Support - The group received government subsidies of HKD 829 thousand under the "Employment Support Scheme" to mitigate the impact of the COVID-19 pandemic[25] Share Capital and Options - The company had 396,736,000 ordinary shares in issue as of September 30, 2022, with a share capital of HKD 3,967,000[41] - No share options were exercised or cancelled during the six months ended September 30, 2022, and 4,000,000 share options expired during the same period[49] - The share options plan details indicate a total of 2,800,000 options available as of September 30, 2022[94] Corporate Governance - The audit committee, consisting of three independent non-executive directors, reviewed the interim financial statements for the six months ending September 30, 2022, and found them compliant with applicable accounting standards and GEM listing rules[108] - The company has adopted the corporate governance code as per GEM listing rules and has complied with it during the six months ending September 30, 2022[101] Future Outlook - Despite the challenges posed by the COVID-19 pandemic, the company remains cautiously optimistic about future performance due to a solid customer base and good reputation in the industry[67] - The company aims to introduce new services and products as a key driver for business growth and to maintain competitiveness in the market[67] - The group continues to focus on enhancing online consultation services and e-commerce platforms for skincare products to adapt to the new normal[64] Miscellaneous - The company did not recommend an interim dividend for the six months ended September 30, 2022, compared to no dividend in 2021[31] - The group had no significant investments or capital asset plans as of September 30, 2022[83] - The group had no significant contingent liabilities as of September 30, 2022[88] - No significant events occurred after the reporting period[60] - The company has not disclosed any new strategies or market expansions in the provided documents[96] - The company has not reported any violations of the trading rules for directors during the six months ending September 30, 2022[104] - No directors or major shareholders were aware of any direct or indirect business interests that could compete with the group as of September 30, 2022[100]